All In Biotech

Drug Trial Radar · NCT01672476

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 293 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

293

Actual

Start

Apr 2012

Primary completion

Mar 2013

Study completion Apr 2013

Sponsor

Sponsor type
Industry
Collaborators
Bucheon St. Mary's Hospital; Konyang University Hospital; Korea University Anam Hospital; National Health Insurance Service Ilsan Hospital; Daegu Fatima Hospital; Dong-A University; Soon Chun Hyang University; Asan Medical Center; Gangnam Severance Hospital; Severance Hospital; Ulsan University Hospital; Kangbuk Samsung Hospital; Sejong General Hospital; Ewha Womans University Mokdong Hospital; Jeju National University Hospital; Hallym University Medical Center; Hanyang University
First posted
Aug 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Conditions

  • Hypertension

Interventions

  • PlaceboDrug

    Placebo

  • ValsartanDrug

    Valsartan 80mg

  • FimasartanDrug

    Fimasartan 30mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the difference of sitting DBPTime frame: After 8 weeks from baseline visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.